arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Neurogene Inc.

NGNE
$30.89 ▼ -2.69 (-8.01%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
63 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

Neurogene Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $696.6M
Dividend Yield
Revenue Growth
Op. Margin None
ROIC -13.3%
FCF / Share $-1.07
Trailing P/E
Price / Book 2.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

63-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-30.93M
↓ -36.6%
FCF / Share Free cash flow per share
$-1.07
↑ +9.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
21
Financial Health
1
Cash Quality
58

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 63 quarters